MedWatch

Morgan Stanley: Still potential in the GN share

Morgan Stanley has included the GN Store Nord share on its list of ‘Best Ideas’ on a global scale. The major bank sees room for additional increases at a time when most other banks are less bullish about the share.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

Genmab søger om ny godkendelse hos EMA

I Europa vil Genmab nu til at have hovedproduktet, Darzalex, godkendt til førstelinjebehandling for knoglemarvskræft. Det udløser en ny milepælsbetaling fra partneren Janssen. (Opdateret 13.35)

Latest Top picks in English

Related articles